AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Further reading == Arthur, Joyce (1996). "Creationism: Bad Science or Immoral Pseudoscience?". Skeptic. 4 (4): 88–93. Archived from the original on March 7, 2012. Montagu, M. F. Ashley, ed. (1984-01-12). Science and Creationism (Kindle ed.). USA: Oxford University Press. ASIN B000QXDJIG. Nelkin, Dorothy (2000) [1986]. The Creation Controversy: Science or Scripture in the Schools. toExcel. ISBN 0-595-00194-7. Numbers, Ronald L. (2006). The Creationists: From Scientific Creationism to Intelligent Design (expanded ed.). Harvard. ISBN 978-0-674-02339-0.
=== Vascularization === It is necessary for a network of blood vessels to be established as soon as possible to provide the growing tissue with nutrients, to take away cellular wastes, and transport new leukocytes to the area. Fibroblasts, the main cells that deposit granulation tissue, depend on oxygen to proliferate and lay down the new extracellular matrix. In vascularisation, also called angiogenesis, endothelial cells quickly grow into the tissue from older, intact blood vessels. These branch out in a systematic way, forming anastomoses with other vessels.
In contrast with EOD, the incidence of LOD has remained unchanged at 0.24-0.26 per 1000 live births in the US. S. agalactiae neonatal meningitis does not present with the hallmark sign of adult meningitis, a stiff neck; rather, it presents with nonspecific symptoms, such as fever, vomiting, and irritability, and can consequently lead to a late diagnosis.
Sources: en.wikipedia.org
Valine (symbol Val or V) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH3+ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO− form under biological conditions), and a side chain isopropyl group, making it a non-polar aliphatic amino acid. Valine is essential in humans, meaning the body cannot synthesize it; it must be obtained from dietary sources which are foods that contain proteins, such as meats, dairy products, soy products, beans and legumes. It is encoded by all codons starting with GU (GUU, GUC, GUA, and GUG).
Thus the one 2s and three 2p orbitals in a carbon atom can be (mathematically) 'mixed' or combined to make four equivalent orbitals (called sp3 hybrid orbitals), which would be the appropriate orbitals to describe carbon compounds such as methane, or the 2s orbital may be combined with two of the 2p orbitals to make three equivalent orbitals (called sp2 hybrid orbitals), with the remaining 2p orbital unhybridized, which would be the appropriate orbitals to describe certain unsaturated carbon compounds such as ethylene. Other hybridization schemes are also found in other types of molecules. Another area which he explored was the relationship between ionic bonding, where electrons are transferred between atoms, and covalent bonding, where electrons are shared between atoms on an equal basis. Pauling showed that these were merely extremes, and that for most actual cases of bonding, the quantum-mechanical wave function for a polar molecule AB is a combination of wave functions for covalent and ionic molecules. Here Pauling's electronegativity concept is particularly useful; the electronegativity difference between a pair of atoms will be the surest predictor of the degree of ionicity of the bond. The third of the topics that Pauling attacked under the overall heading of "the nature of the chemical bond" was the accounting of the structure of aromatic hydrocarbons, particularly the prototype, benzene. The best description of benzene had been made by the German chemist August Kekulé.
==== India ==== On February 24, 2011, Dunkin' Donuts signed a master franchise agreement with Indian food service company Jubilant FoodWorks to operate the brand in India. Jubilant FoodWorks opened the country's first Dunkin' Donuts outlet at Connaught Place, New Delhi in April 2012. In November 2014, Dunkin' Donuts opened its first store in Kanpur, Uttar Pradesh inside Z Square Mall. There were 32 Dunkin' Donuts outlets across 10 Indian cities as of December 31, 2019. On March 30, 2026, it was announced that Jubilant FoodWorks had decided not to renew development and operation agreements of Dunkin' Donuts in India. The agreement is to expire on December 31, 2026.
Sources: en.wikipedia.org
=== Performance === The theme that structures the novel is that of performance. As the book opens, Kaname is gently pressuring his wife, Misako, into meeting her father and his mistress at a bunraku performance. The "old man" (he is fifty-six or fifty-seven) has a deep interest in many forms of traditional Japanese performance, from samisen and song to rustic puppets. But these are only the framing performances, as the life being led by Kaname and Misako is itself a performance, as Tanizaki reminds us several times. Even their son, Hiroshi, becomes a performer. The closing words of the novel transform a wooden doll into a woman. In many ways, from local accent to clothing, the central characters assume roles they need and can hardly bear, making the story a series of mirrors in which artifice and reality become interwoven.
=== Bone marrow suppression === Chloramphenicol may cause bone marrow suppression during treatment; this is a direct toxic effect of the drug on human mitochondria. This effect manifests first as a fall in hemoglobin levels, which occurs quite predictably once a cumulative dose of 20 g has been given. The anaemia is fully reversible once the drug is stopped and does not predict future development of aplastic anaemia. Studies in mice have suggested existing marrow damage may compound any marrow damage resulting from the toxic effects of chloramphenicol.
===== Rpn1 ===== Ubiquitin binds Rpn1 via two sites, termed the T1 and T2 sites that were identified using NMR. Rpn1 also provides a docking site for Ubp6. The affinities for ubiquitin for these receptors in isolation has been measured through a variety of methods. They are all in the micromolar range, however a substrate that has both a ubiquitin signal and an unstructured region has a Michaelis menten constant in the hundreds of nanomolar range, suggesting that the unstructured region in key in engaging a substrate.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.